Omeros (Omeros) Float Percentage Of Total Shares Outstanding : 95.64% (As of Apr. 30, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Omeros's float shares is 55.42 Mil. Omeros's total shares outstanding is 57.94 Mil. Omeros's float percentage of total shares outstanding is 95.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Omeros's Insider Ownership is 4.15%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Omeros's Institutional Ownership is 21.14%.

Omeros Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Omeros's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	55.42	/	57.94
	=	95.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omeros (Omeros) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Executives

Demopulos Gregory A Md	director, 10 percent owner, officer: Chairman, CEO & President	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen	officer: VP Finance and CAO	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo	officer: See Remarks	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol	director	201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon	officer: VP Patent and General Counsel	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah	director	C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet	director	1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347